Irish pharmaceuticals’ dependence on imported raw materials means the impact on GDP of the expiry of key global patents will be far less than has been feared, according to chief economist with Davy Stockbrokers Conall MacCoille.

SOME €19 billion of Irish pharmaceutical exports may be impacted by the expiration of patents on a number of blockbuster medicines produced here.